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Summary
Using a sample of 2925 stroke-free participants drawn from a national population-based study, we
examined cross-sectional associations of obstructive sleep apnea risk (OSA) with cognition and
quality of life and whether these vary with age, while controlling for demographics and co-
morbidities. Included participants from the REasons for Geographic And Racial Differences in
Stroke Study were aged 47-93. OSA risk was categorized as high or low based on responses to the
Berlin Sleep Questionnaire. Cognitive function was assessed with standardized fluency and recall
measures. Depressive symptoms were assessed with the four-item Center for Epidemiologic
Studies Depression Scale. Health-related Quality of Life (HRQoL) was assessed with the Medical
Outcomes Study Short Form-12 (SF-12). MANCOVA statistics were applied separately to the
cognitive and quality of life dependent variables while accounting for potential confounders
(demographics, co-morbidities). In fully adjusted models, those at high risk for OSA had
significantly lower cognitive scores (Wilks’ Lambda = 0.996, F(3, 2786) = 3.31, p < .05) and
lower quality of life (depressive symptoms and HRQoL) (Wilks’ Lambda = 0.989, F(3, 2786) =
10.02, p < .0001). However, some of the associations were age-dependent. Differences in
cognition and quality of life between those at high and low obstructive sleep apnea risk were most
pronounced during middle age, with attenuated effects after age 70.
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Recent studies have shown an association between obstructive sleep apnea (OSA) and
cognitive impairment. Research examining cognition in OSA has shown impairments in
general intellectual functioning, attention/concentration, vigilance, memory, and particularly
executive functioning (Beebe et al., 2003; Sateia, 2003). Frontal lobe (i.e., executive)
dysfunction has been proposed as the primary manifestation of OSA (Beebe & Gozal, 2002).
This hypothesis is also supported by imaging studies (Zimmerman & Aloia, 2006). Factors
often associated with OSA, such as psychological distress and co-morbid medical
conditions, are also well-established correlates of executive dysfunction (O’Hara et al.,
2006; Waldstein et al., 2001), and may substantially contribute to cognitive dysfunction in
OSA. In addition, demographic characteristics may function as risk or protective factors for
cognitive decline in this population. Although these factors have been suggested as possible
contributors to this relationship, few studies have adequately controlled for these factors in
analyses of OSA and cognition.
It is of particular interest to determine whether the cognitive and quality of life sequelae of
OSA vary with age. Indeed, a recent review of OSA in adults reported that the increased risk
of morbidity and mortality associated with OSA peaks at approximately 55 years of age
(Lurie, 2011). However, a recent longitudinal study with an older population (mean age =
82) also found increased risk of mild cognitive impairment or dementia in participants with
sleep-disordered breathing versus those without this condition (Yaffe et al., 2011). The study
adjusted for demographic characteristics (i.e., age, race, education), comorbid conditions
(i.e., diabetes, hypertension), and antidepressant use, but the results were limited to older
women, and there was no examination of self-reported quality of life.
The purpose of the present study was to examine OSA and its association with depressive
symptoms, quality of life, and cognitive function while controlling for other factors that may
contribute to this association (i.e., age, sex, education, race, diabetes, dyslipidemia). This
study extends prior research by utilizing a large national sample of black and white
individuals from the Reasons for Geographic and Racial Differences in Stroke (REGARDS)
study, thus allowing simultaneous control of several variables while ensuring sufficient
statistical power. We posited that, after controlling for potential confounders, cognitive
performance would be lower, depressive symptoms would be more severe, and health-
related quality of life (HRQoL) would be poorer in those at high versus low risk for OSA.
Methods
Design and Procedures
The REGARDS study aims to determine the causes of higher stroke mortality among black
Americans and residents of the southern Stroke Belt (i.e., Alabama, Arkansas, Georgia,
Louisiana, Mississippi, North Carolina, South Carolina, and Tennessee). Mail and telephone
contact methods were used to recruit the cohort of US adults 45 years of age or older from
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lists of U.S. residents purchased from Genesys, Inc. A total of 30,239 participants were
recruited from January 2003 to October 2007. The institutional review boards on human
research at all participating institutions approved the study. At baseline, participants
answered demographic and medical history questions during a computer-assisted telephone
interview. During a home visit they provided appropriate written informed consent,
anthropometric measurements, blood pressure, blood and urine, medication inventory, and
an electrocardiogram. Participants are followed by telephone twice per year. If a participant
reports a suspected stroke, his/her medical records are obtained and adjudicated by study
physicians to confirm or refute stroke incidence.
Data for this report were drawn from a quarterly data freeze on 10/01/2010. For the current
analyses of sleep apnea risk, cognitive function, and quality of life variables (depression and
HRQoL), we restricted our analyses to participants who had completed (1) the sleep apnea
module, which was administered to each participant beginning in September 2008 at the first
available six-month follow up call, (2) quality of life measurements assessed at baseline
interview, and (3) an expanded cognitive battery including verbal fluency and word list
learning and recall. The components of this expanded battery were implemented into the
REGARDS follow-up call sequence over time. The battery was not administered as a unit
until May, 2008, during participants’ scheduled follow up calls at months 18, 42, 66, and
every 2 years thereafter (with timing depending upon the date of initial enrollment). For our
purposes, we were interested in using concurrently administered cognitive assessments that
were temporally contiguous to administration of the sleep apnea module (defined as within
365 days). To meet this criterion, we included only those participants who had completed
the expanded cognitive battery in May 2008 or later and the sleep apnea module in
September 2008 or later. The median number of days between these assessments was 192,
and the mean was 162.6 (s.d. 138.3). With these restrictions, as well as the exclusion of
participants with self-reported stroke at baseline and/or with confirmed incident stroke prior
to their first expanded cognitive assessment in 2008 or later, 2925 participants were
available for inclusion in these analyses.
Measures
Demographics—Participants’ age, sex, race (black, white), and educational attainment
(less than high school, high school graduate, some college or vocational training, or college
graduate) were obtained by self-report.
Obstructive Sleep Apnea (OSA)—The Berlin Sleep Questionnaire (BSQ; Netzer et al.,
1999) includes 3 symptom categories of risk for OSA: (1) snoring (5 items), (2) daytime
sleepiness (3 items), and (3) hypertension/body mass index (BMI) (2 items). Hypertension
was defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or self-reported use of
antihypertensive medications. BMI was calculated from measured height and weight. Per the
standard protocol, participants were placed into two dependent variable categories based on
their responses: (1) High risk for OSA diagnosis and (2) Low risk for OSA diagnosis.
Respondents were considered high risk for OSA if they met criteria in 2 of the 3 symptom
categories (Netzer et al., 1999), as indicated by ≥2 positive responses in symptom category
1, ≥2 in category 2, and ≥1 in category 3 (or a BMI >30). Those with sufficient symptoms in
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none or only one of the symptom categories were considered low risk for OSA. The BSQ
has been found to predict elevated respiratory distress indices in high risk respondents with a
sensitivity of 0.86, specificity of 0.77, and a positive predictive value of 0.89 (Netzer et al.,
1999). Preceding the BSQ questions was a question regarding diagnosis of sleep apnea,
followed by questions about treatment for those who reported having been given the
diagnosis. Because studies have shown that Continuous Positive Airway Pressure (CPAP)
treatment may be associated with improvement in cognition (Ferini-Strambi et al., 2003;
Feuerstein et al., 1997), depressive symptoms (Kawahara et al., 2005; Means et al., 2003),
and HRQoL (Siccoli et al., 2008), we examined the impact of self-reported OSA treatment
as a modifier of outcomes among those who self-reported a physician diagnosis of sleep
apnea.
Cognitive Function
Verbal Memory (Word List Delayed Recall): Word List Delayed Recall is a component
of Word List Learning from the Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD) battery. The list learning portion consists of three learning trials of 10
semantically-unrelated words which are presented in a fixed order that varies across the
three trials (Morris et al., 1989). In REGARDS, this measure is administered according to
the standard protocol, with two modifications for telephone administration: (1) no visual
presentation of the stimuli and (2) participants are instructed not to write anything down. For
delayed recall, participants are asked to freely recall as many of the ten words as possible
after an approximate 5-minute delay. Non-cognitive interview questions are asked during
the delay. Scores range from 0 to 10.
Executive Function (Animal Fluency and Letter Fluency): The fluency measures were
administered according to standardized scripts (Strauss et al., 2006) which require
participants to name as many words beginning with the letter ‘F’ as they can, and
subsequently, to name as many animals as they can. The time allotted for each measure is 1
minute. Raw scores on each consist of the total number of valid responses produced by each
participant in 60 seconds. Responses were recorded on audio. WAV files that were later
scored by trained college-educated scorers with computer-assisted scoring programs
developed for this purpose. Inter-scorer agreement on scores for these measures was
excellent (kappas >.95) for both.
Quality of Life—For the purposes of this study, we included depressive symptoms and
mental and physical aspects of HRQoL under the broader designation “quality of life”.
Depressive Symptoms: The 4-item Center for Epidemiological Studies - Depression Scale
(CES-D-4; Melchior et al., 1993) was derived from the original 20-item CES-D (Radloff,
1977) to identify the presence of depressive symptoms. Reliability and validity are similar to
that of the original instrument (Melchior et al., 1993). Responses to each item are recorded
on a 4-point (0-3) scale for symptoms experienced in the preceding week. Scores range from
0 to 12, with higher scores indicating endorsement of more depressive symptoms, and a
score of ≥ 4 indicating elevated psychological distress (Melchior et al., 1993). For the
present study, scores were analyzed on a continuum from 0 to 12.
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Health-related Quality of Life (HRQoL): HRQoL was assessed utilizing responses to The
Medical Outcomes Study Short Form-12 (SF-12). Responses to the SF-12 produce two
scales, the Mental Component Summary (MCS-12) indicating mental health and well-being,
and the Physical Component Summary (PCS-12) indicating physical health and well-being
(Ware et al., 1996). The scores for each scale range from 0 to 100, with higher scores
indicative of better functioning. The MCS-12 and PCS-12 scores have been found to closely
approximate their equivalents in the SF-36 (Ware et al., 1996).
Diabetes and Dyslipidemia—Participants were categorized as diabetic if they met one
or more of the following criteria: fasting glucose of ≥ 126 mg/dL, non-fasting glucose of ≥
200 mg/dL, or use of diabetic medication or insulin. Dyslipidemia was defined by one or
more of the following: total cholesterol of ≥ 240 mg/dL, LDL ≥ 160 mg/dL, HDL ≤ 40
mg/dL, or use of lipid modifying medication. REGARDS baseline BMI and hypertension
measurements were not included as comorbid conditions, as these conditions were also
assessed as part of the BSQ definition of risk for OSA.
Statistical Analyses
Pearson chi-square tests were used to assess differences of proportions in categorical
variables across BSQ groups, and t-tests were used to identify differences in means for
continuous variables. The three cognitive outcomes were analyzed simultaneously in
incremental MANOVA/MANCOVA models, as were the three quality of life outcome
variables (i.e., depressive symptoms, HRQoL mental components, HRQoL physical
components). Planned univariate analyses were also conducted to examine the relationships
between BSQ group and each of the six outcomes of interest utilizing incremental ANOVA/
ANCOVA models (separately for each outcome). Unadjusted univariate analyses were
performed, followed by adjustment for demographic variables (age, sex, race, educational
attainment). Co-morbid medical conditions (diabetes, dyslipidemia) were included in a third
and final model. Interactions between BSQ group and model covariates were evaluated and
interaction plots were constructed for significantly interacting variables. In a sensitivity
analysis, we replicated these models in a sample restricted to participants at highest OSA
risk (BSQ positive in all three symptom categories) and lowest OSA risk (BSQ negative in
all three symptom categories) (total sensitivity analysis n = 733). Analyses were conducted
using SAS version 9.2 (SAS Institute Inc, Cary, NC).
Results
The mean age of the sample at the time of completion of the BSQ was 67.5 years, with a
range of 47-93 years. Approximately 57% of the sample were women, and 65% were white.
Over 90% of the sample had an education level of high school or above, with only 8%
having less than a high school education. Participants with high OSA risk were younger on
average, more likely to be male, and more likely to have diabetes and dyslipidemia than
those at low risk (Table 1).
A previous diagnosis of OSA was self-reported by 11.6% of this sample, and 10.1%
reported having been treated. Preliminary analyses of participants who reported an OSA
diagnosis revealed no significant association between OSA treatment and OSA risk (p =
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0.618). Additional analysis with OSA treatment as a predictor of outcome revealed little
difference in cognitive outcome as compared with the use of OSA risk groups; therefore,
treatment status was not included as a covariate in subsequent analyses. However, those who
were not being treated and were at low risk for OSA reported significantly better mood and
HRQoL at younger ages versus the treated or high risk untreated groups (at age 65 Wilks’
Lambda = 0.965, F(3, 2784)=33.97, p < .0001).
MANOVA results assessing the cognitive measures simultaneously showed a marginal
association between OSA risk and cognitive function, which became significant in
demographics-adjusted and co-morbidity adjusted MANCOVA models (Table 2).
Those at high risk for OSA performed more poorly (Table 3; Wilks’ Lambda = 0.996, F(3,
2786) = 3.31, p < .05). Simultaneous assessment of depressive symptoms and HRQoL
indices also yielded a significant difference by OSA risk category, with those at high risk
showing more depressive symptoms and worse HRQoL (Table 3; Wilks’ Lambda = 0.989,
F(3, 2786) = 10.02, p < .0001).
Follow-up univariate analyses (ANOVA/ANCOVA) of each discrete cognitive and quality
of life outcome (depressive symptoms, mental components, physical components), adjusted
for demographics and co-morbid conditions, generally revealed OSA risk category to be a
significant predictor of score differences. Specifically, the following indices were
significantly worse among those at high risk for OSA: Animal Fluency (fully adjusted F(1,
2788) = 8.09, p = .0045), CESD-4 (fully adjusted F(1, 2788) = 13.21, p= .0003), HRQoL
MCS-12 (fully adjusted F(1, 2788) = 5.47, p = .0194), and HRQoL PCS-12 (fully adjusted
F(1, 2788) = 20.79, p < .0001). OSA risk did not predict Letter Fluency performance (fully
adjusted F(1, 2788) = 1.62, p = .20) and marginally predicted Delayed Recall performance
(fully adjusted F(1, 2788) = 3.77, p = .052), although adjustment for demographics only did
result in significant differences in Delayed Recall by OSA risk (F(1, 2916) = 4.41, p = .036).
There was a significant OSA risk by age interaction affecting several of the outcome
variables, specifically, Animal Fluency (fully adjusted F(1, 2788) for interaction term =
8.18, p = .004), CESD-4 (fully adjusted F(1, 2788) for interaction = 9.32, p = .002), and
HRQoL PCS-12 (fully adjusted F(1, 2788) for interaction = 13.84, p = .0002). Individuals at
high risk for OSA had lower Animal Fluency scores than their low risk peers at younger
ages (Figure 1). However, the trend for lower animal fluency scores at older ages was
steeper for those with low OSA risk than for those with high risk, resulting in a crossover at
approximately age 70. Younger high risk individuals reported more depressive symptoms
than their low risk counterparts (Figure 2); however, at older ages, high risk individuals’
report of depressive symptoms did not differ from those of low risk participants. A similar
trend was found for physical well-being (Figure 3) and mental well-being, although for the
latter index the age by OSA risk interaction was not statistically significant. Physical well-
being was more negatively perceived among younger individuals at high risk for OSA
versus older individuals at high risk.
In sensitivity analyses restricted to those at highest and lowest OSA risk, the fully adjusted
models including gender, education, race, diabetes, and dyslipidemia underscored the
Addison-Brown et al. Page 6
J Sleep Res. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
primary study results with respect to the main and interactive effects of OSA risk and age on
both cognitive and quality of life outcomes (MANOVA p values for OSA risk = .007 and .
0001 for cognition and quality of life, respectively; for age, p values = .0001 for both
outcomes; and for the interaction of OSA risk and age, p values = .007 and .03 respectively).
Univariate parameter estimates indicated that those at highest OSA risk scored on average
16.12 points lower than those at no risk on the animal fluency measure; 3.15 points higher
on the CES-D-4, indicating more depressive symptoms; and 23.86 and 23.31 points lower
on the SF-12 PCS and MCS scores respectively, indicating markedly lower HRQoL. These
effects were pronounced at younger ages and were diminished to no difference or virtually
no difference at older ages, with older age conferring modest but statistically significant
protective effects in those at high OSA risk (i.e., less than 0.5 points better scores on animal
fluency and MCS scores per year of age).
In post hoc analyses conducted to examine the possibility of healthy survivor effects, we
found that older participants were less likely to be classified as high risk for OSA (p
<0.0001). The percentage of participants classified as high risk OSA within age strata were:
27% of participants <50 years of age (13 of 47 participants), 36% aged 50-59 (157 of 441),
30% aged 60-69 (380 of 1,248), 22% age 70-79 (204 of 922), 11% aged 80-89 (28 of 255),
and 0% aged 90+ (0 of 12).
Discussion
In this population-based sample, 27% of eligible participants were classified as high risk for
OSA, consistent with previous studies utilizing the Berlin Sleep Questionnaire (Netzer et al.,
2003). Although neuropsychological deficits, depressed mood, and decreased quality of life
have been identified previously in individuals with OSA, demographic factors and co-
morbid conditions have complicated interpretation of findings. The current study had ample
power to control for age, sex, race, education, diabetes, and dyslipidemia. Compared to
recent research controlling for similar factors (Yaffe et al., 2011), our study is unique in its
balanced sampling of men and women, its substantial proportion of black participants, and
its inclusion of middle aged adults . Our results suggest that OSA is associated with poorer
cognition and quality of life even after adjusting for factors that have not been adequately
investigated in prior studies.
Consistent with prior research, OSA significantly predicted differences in executive function
as assessed with Animal Fluency (Incalzi et al., 2004), and marginally significant
differences in memory as assessed with Delayed Recall (Boland et al., 2002) in fully
adjusted models. However, unlike previous studies (Incalzi et al., 2004; Netzer et al., 1999),
we did not find an association between OSA risk and Letter Fluency performance, perhaps
due to differing OSA case finding strategies, differences in test administration (e.g., our
administration of one letter versus three letters as in Incalzi et al., 2004), or selection factors
including those associated with clinical versus epidemiological samples. On the other hand,
some clinical studies of OSA (eg. Naismith et al 2004) have reported no association of either
letter or semantic fluency performance with certain aspects of OSA, including sleepiness
and hypoxemia. OSA may have differential effects on various aspects of cognitive
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performance depending on the primary symptoms involved, duration of symptoms, and
symptom severity (Quan et al., 2006).
Age interacted with OSA risk in determining executive function performance as well as
quality of life, with fewer depressive symptoms and better HRQoL among older
participants. Our finding that OSA risk is less related to quality of life among older adults
mirrors previous research (Martinez-Garcia, 2009), and this phenomenon likely is multiply
determined. First, older adults who do not die or become lost to follow-up during studies
represent “healthy survivors.” Consistent with this interpretation, our post hoc analyses
confirmed that high risk OSA classification decreased with age. Another plausible
explanation is differential misclassification due to self-report, with older adults tending to
underreport subjective depressive symptoms (O’Hara et al., 2006). It is also possible that the
symptoms represented by the Berlin Questionnaire (e.g., hypertension, snoring, daytime
sleepiness) reflect different processes in older people than younger people, some of which
may be unrelated to OSA. The mental and physical HRQoL variables used in this study may
not be as salient once individuals exit the work force. Interestingly, some research suggests
that functional capacity and health status are not requisites for quality of life in older adults.
Rather, quality of life is evaluated relative to expectations, and expectations for mental and
physical function may decline with advancing age (Dempster & Donnelly, 2002). Social
comparison theory suggests that older adults use a “downward” comparison strategy,
whereby they compare themselves with individuals in worse health, consequently perceiving
their own situations more positively (Beaumont & Kenealy, 2004; DiLorenzo et al., 2009).
Limitations and Conclusions
The brevity of the cognitive evaluation in the present study is a limitation; however, our
selection of measures was dictated by the scope of the population-based sample, affording a
large sample that provided adequate data to control for key covariates. Another potential
limitation is the administration of cognitive assessment measures by telephone. However,
comparisons of in-person and telephone administration of measures similar to those used in
this study suggest comparable results (Unverzagt et al., 2007), and the fluency assessments
we used have been administered by telephone in other studies. Therefore, telephone
administration appears to be a useful tool for gathering of large amounts of data without
sacrificing accuracy.
The Berlin Sleep Questionnaire used to stratify participants by OSA risk category includes
hypertension and body mass index in its criteria for group placement. We were therefore
unable to use these comorbidities as covariates, even though both may be important
contributors to cognitive function in particular. Future studies utilizing clinical diagnostic
techniques will allow direct examination of these variables. Use of the BSQ is a convenient
method for calculating OSA risk but lacks the precision of polysomnography, which likely
diminished our estimates of the true relationship of OSA to cognitive function and quality of
life. Even so, our less cumbersome OSA measure allowed for a large community-dwelling
sample, which represents a significant contribution of the current study.
We found only minimal differences in outcomes based on CPAP treatment. Noncompliance,
commonly reported in OSA literature (Weaver & Grustein, 2008), is one possible
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explanation for the absence of differences in cognition and HRQoL based on treatment.
Previous studies examined individuals with moderate to severe OSA (Kawahara et al., 2005;
Siccoli et al., 2008) and/or required formal diagnosis with polysomnography (Means et al,
2003). Such samples may benefit more from treatment compared to a community-dwelling
sample drawn from an epidemiological sample such as ours, which likely includes
individuals with less severe OSA. Duration of OSA also is likely an important marker of
susceptibility to cognitive sequelae, and we did not have information regarding duration of
symptoms or of treatment among those with self-reported diagnosis of OSA.
Finally, the current analyses are cross-sectional, limiting the extent to which conclusions can
be drawn. Longitudinal approaches could be used to identify risk factors for OSA, establish
the temporal relationship between markers for OSA and cognitive outcomes, and examine
effects of OSA treatment. The REGARDS cohort lends itself to this type of approach in the
future.
Despite these limitations, we were able to confirm OSA’s effect on cognition, depressive
symptoms, and HRQoL while accounting for potentially confounding demographic and co-
morbid factors. However, we also found differential effects based on age, with more
detrimental correlates of OSA in younger versus older adults, particularly in terms of mood
and HRQoL. The direction of this finding is consistent with a reported age threshold of 55
years as the peak after which the heightened OSA-associated risk of morbidity and mortality
declines (Lurie, 2011). Therefore, accurate detection and treatment of OSA in younger
adults may be particularly important. Finally, although it appears that older adults at high
risk for OSA may perceive better quality of life than their younger peers despite similar
symptoms, it is also possible that self-report symptom questionnaires may fail to capture
symptoms indicative of distress among older adults. Age differences deserve further scrutiny
in future studies of OSA and quality of life.
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Figure 1. Interaction of Age and Obstructive Sleep Apnea Risk on Animal Fluency Score
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Figure 2. Interaction of Age and Obstructive Sleep Apnea Risk on Four-item Center for
Epidemiological Studies Depression Score
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Figure 3. Interaction of Age and Obstructive Sleep Apnea Risk on Physical Component Score of
Short Form - 12 Health-related Quality of Life
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Table 1
Demographic and co-morbid characteristics of study population by risk for Obstructive Sleep Apnea (OSA).
OSA Risk
Variable Overall n=2925 High Risk+ n=782 Low Risk n=2143 p-value
Mean (sd) Age at sleep questionnaire 67.53 (8.73) 65.30 (7.95) 68.34 (8.86) <0.0001
N (%) male 1246 (42.60) 357 (45.65) 889 (41.48) 0.0436
N (%) Education
 Less than high school 234 (8.00) 65 (8.31) 169 (7.89)
 High school graduate 755 (25.81) 203 (25.96) 552 (25.76) 0.7691
 Some college 812 (27.76) 225 (28.77) 587 (27.39)
 College graduate and above 1124 (38.43) 289 (36.96) 835 (38.96)
N (%) Black 1016 (34.74) 277 (35.42) 739 (34.48) 0.6374
N (%) Diabetes* 539 (18.97) 199 (26.18) 340 (16.34) <0.0001
N (%) Dyslipidemia** 1656 (58.35) 510 (67.11) 1146 (55.15) <0.0001
*
Diabetic if fasting glucose >=126 mg/dL / non-fasting glucose >=200 mg/dL or on diabetic medication or insulin
**
Dyslipidemia if Total cholesterol C >=240 mg/dL or LDL >=160 mg/dL or HDL <= 40 mg/dLor on lipid-lowering medication
+
Respondents were considered high risk for Obstructive Sleep Apnea (OSA) if they met criteria in 2 or 3 of the three symptom categories of the
Berlin Sleep Questionnaire, while those with symptoms in none or only one of the symptom categories were considered low risk for OSA.
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